Teva Pharmaceutical Industries Stock Forecast
NYSE: TEVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TEVA analyst consensus
Consensus (15 analysts)
buy
Avg. price target
$50.29+28.19%
- Strong buy 4
- Buy 9
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 15 Wall Street analysts covering Teva Pharmaceutical Industries (2026-11-19), 13 rate the stock a buy or strong buy, 2 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $50.29, with a high estimate of $57.00 and a low estimate of $42.12. The average target implies upside of 28.2% from the current price of $39.23.
The spread between the highest and lowest targets is 35.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for TEVA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 4 | 27% |
| Buy | 9 | 60% |
| Hold | 2 | 13% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-11-19.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $42.12 | +7.37% |
| Average target | $50.29 | +28.19% |
| High target | $57.00 | +45.30% |